Combined inhibition of 20-hydroxyeicosatetraenoic acid formation and of epoxyeicosatrienoic acids degradation attenuates hypertension and hypertension-induced end-organ damage in Ren-2 transgenic rats. Clin Sci (Lond) 2010 Feb 23;118(10):617-32
Date
01/07/2010Pubmed ID
20050826Pubmed Central ID
PMC2854172DOI
10.1042/CS20090459Scopus ID
2-s2.0-77954063347 (requires institutional sign-in at Scopus site) 44 CitationsAbstract
Recent studies have shown that the renal CYP450 (cytochrome P450) metabolites of AA (arachidonic acid), the vasoconstrictor 20-HETE (20-hydroxyeicosatetraenoic acid) and the vasodilator EETs (epoxyeicosatrienoic acids), play an important role in the pathophysiology of AngII (angiotensin II)-dependent forms of hypertension and the associated target organ damage. The present studies were performed in Ren-2 renin transgenic rats (TGR) to evaluate the effects of chronic selective inhibition of 20-HETE formation or elevation of the level of EETs, alone or in combination, on the course of hypertension and hypertension-associated end-organ damage. Both young (30 days of age) prehypertensive TGR and adult (190 days of age) TGR with established hypertension were examined. Normotensive HanSD (Hannover Sprague-Dawley) rats served as controls. The rats were treated with N-methylsulfonyl-12,12-dibromododec-11-enamide to inhibit 20-HETE formation and/or with N-cyclohexyl-N-dodecyl urea to inhibit soluble epoxide hydrolase and prevent degradation of EETs. Inhibition in TGR of 20-HETE formation combined with enhanced bioavailability of EETs attenuated the development of hypertension, cardiac hypertrophy, proteinuria, glomerular hypertrophy and sclerosis as well as renal tubulointerstitial injury. This was also associated with attenuation of the responsiveness of the systemic and renal vascular beds to AngII without modifying their responses to noradrenaline (norepinephrine). Our findings suggest that altered production and/or action of 20-HETE and EETs plays a permissive role in the development of hypertension and hypertension-associated end-organ damage in this model of AngII-dependent hypertension. This information provides a basis for a search for new therapeutic approaches for the treatment of hypertension.
Author List
Certíková Chábová V, Walkowska A, Kompanowska-Jezierska E, Sadowski J, Kujal P, Vernerová Z, Vanourková Z, Kopkan L, Kramer HJ, Falck JR, Imig JD, Hammock BD, Vanecková I, Cervenka LMESH terms used to index this publication - Major topics in bold
8,11,14-Eicosatrienoic AcidAmides
Angiotensin II
Animals
Antihypertensive Agents
Blood Pressure
Drug Evaluation, Preclinical
Hydroxyeicosatetraenoic Acids
Hypertension
Male
Multiple Organ Failure
Norepinephrine
Rats
Rats, Sprague-Dawley
Rats, Transgenic
Renal Circulation
Sulfones
Vasoconstrictor Agents
